After years of stagnation, the iNTS vaccine pipeline is gaining momentum, with early-stage approaches emerging. Despite high disease burden and rising antimicrobial resistance, particularly in sub-Saharan Africa, no licensed vaccines exist, underscoring a critical gap and need for innovation and clearer pathways to licensure.
The end of clinical failure in Alzheimer’s has unlocked a market of historic proportions. With 140+ therapies in development, clinical success is now just the price of entry. At Shift Health, we believe leadership requires a transition “beyond the molecule” toward an ecosystem-wide strategy focused on four critical pillars.
Alzheimer’s disease represents one of the most urgent and complex challenges facing healthcare systems worldwide. The emergence of disease-modifying therapies, together with advances in digital diagnostic tools and blood-based biomarkers, signals a new era of possibility—one that demands bold action and system-wide readiness.
Ontario’s life sciences sector is a global leader in research and talent—but a critical shortage of seed-stage capital is limiting its ability to commercialize innovation and retain homegrown companies. A new report from Life Sciences Ontario and Shift Health outlines the urgency of this challenge and presents a clear roadmap for change.
Recognizing the potential for CAR T to transform the way we treat some of the most complex conditions, Shift Health assembled a multidisciplinary panel of experts to develop concrete recommendations to prepare Canadian healthcare systems to enhance equitable access to this innovative treatment.
This peer-reviewed paper presents solutions to alleviate health system capacity constraints for retinal care.
Impact assessments help funders and health research organizations evaluate progress and performance of their investments and optimize plans for long-term success.
The report is informed by the findings from a national survey of life sciences organizations and focus groups with diverse individuals working in the sector.
We share key insights for pharmaceutical companies bringing new products to the Canadian market, highlighting considerations for the current and future hospital formulary decision-making landscape.